Nanobiotix S.A. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K is a report of a foreign private issuer filed by Nanobiotix S.A. for the month of October 2025. The filing, dated October 31, 2025, serves to incorporate by reference a press release issued on the same date (Exhibit 99.1). The registrant files annual reports under Form 20-F.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document acts as a conduit for a press release rather than a financial statement containing quantitative data.
Material Changes
The filing text does not provide a clear value regarding material changes versus the prior comparable period. The content is limited to the procedural inclusion of an external press release.
Guidance, Outlook, and Risks
Specific details regarding guidance, outlook, management commentary, risks, contingencies, or unusual items are not present in the provided text. These details are contained within the attached Exhibit 99.1 (Press Release), the content of which is not included in the input.
Key Facts for Investor Verification
- Verify the full content of the press release dated October 31, 2025, referenced as Exhibit 99.1.
- Confirm the specific operational or clinical developments announced in the press release, as the Form 6-K itself contains no substantive details.
- Note that the report was signed by Bart Van Rhijn, Chief Financial Officer.